Compare APAM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | TRVI |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2011 | 2019 |
| Metric | APAM | TRVI |
|---|---|---|
| Price | $39.34 | $17.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $43.00 | $21.55 |
| AVG Volume (30 Days) | 930.0K | ★ 3.0M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.81% | N/A |
| EPS Growth | 10.66 | ★ 31.91 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $1,196,688,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $5.05 | N/A |
| P/E Ratio | $50.68 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $33.96 | $6.55 |
| 52 Week High | $48.46 | $20.22 |
| Indicator | APAM | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 64.04 | 50.62 |
| Support Level | $34.59 | $10.07 |
| Resistance Level | $40.50 | $20.19 |
| Average True Range (ATR) | 0.94 | 1.40 |
| MACD | 0.24 | -0.23 |
| Stochastic Oscillator | 77.65 | 27.89 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.